Vita Life Sciences Dividends and Buybacks
Dividend criteria checks 4/6
Vita Life Sciences is a dividend paying company with a current yield of 4.44% that is well covered by earnings.
Key information
4.4%
Dividend yield
-2.0%
Buyback Yield
| Total Shareholder Yield | 2.5% |
| Future Dividend Yield | n/a |
| Dividend Growth | 10.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 63% |
Recent dividend and buyback updates
Recent updates
Weekly Picks: 💊 VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns
Jun 17
Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges
Vita Life Sciences (ASX: VLS) – A Solid Business Seeking Renewed MomentumVita Life Sciences (ASX: VLS) is a well-established healthcare company specializing in the formulation, packaging, distributionImproved Earnings Required Before Vita Life Sciences Limited (ASX:VLS) Shares Find Their Feet
Feb 21
Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 23Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035
Aug 28Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Mar 22Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06
Mar 14Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 28A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)
Dec 20Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?
Aug 24If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late
May 14Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?
Mar 18Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?
Feb 17Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?
Jan 20Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching
Dec 22Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Nov 19
Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares
Jul 14Stability and Growth of Payments
Fetching dividends data
Stable Dividend: VLS's dividends per share have been stable in the past 10 years.
Growing Dividend: VLS's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Vita Life Sciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (VLS) | 4.4% |
| Market Bottom 25% (AU) | 2.5% |
| Market Top 25% (AU) | 6.1% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (VLS) (up to 3 years) | n/a |
Notable Dividend: VLS's dividend (4.44%) is higher than the bottom 25% of dividend payers in the Australian market (2.48%).
High Dividend: VLS's dividend (4.44%) is low compared to the top 25% of dividend payers in the Australian market (6.09%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (63.3%), VLS's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (92.4%), VLS's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/11 03:23 |
| End of Day Share Price | 2025/07/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vita Life Sciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aidan Brooksby | Select Equities Pty Ltd |
| Shane Storey | Wilsons Advisory and Stockbroking Ltd. |